Advertisement

Submit Manuscripts
Author Information
Subscribe/Renew
Order Reprints
Email Alerts
Feedback
RSS Feed
CME

About the Journal
Editorial Board & Staff

About JACC CME
Hardware/Software Requirements
Contact Us
Policy on Privacy and Confidentiality
Copyright Information

JACC Imaging Homepage JACC Interventions Homepage
Still not a subscriber to JACC Imaging or JACC Interventions?
Click here
to sign up now!

ACC.org
Cardiosmart
Cardiosource
CVN
Imaging Library
JACC Imaging
JACC Interventions

Click here for more guidelines.
2009 Focused Updates: ACC/AHA Guidelines for STEMI and ACC/AHA/SCAI Guidelines for PCI
2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery
ACC 2009 Advocacy Position Statement: Principles for Comparative Effectiveness Research
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2007; 49:657-666, doi:10.1016/j.jacc.2006.10.050 (Published online 25 January 2007).
© 2007 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
j.jacc.2006.10.050v1
49/6/657    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (94)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bliden, K. P.
Right arrow Articles by Gurbel, P. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Bliden, K. P.
Right arrow Articles by Gurbel, P. A.

CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY

Increased Risk in Patients With High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary Intervention

Is the Current Antiplatelet Therapy Adequate?

Kevin P. Bliden, BS, Joseph DiChiara, BS, Udaya S. Tantry, PhD, Ashwani K. Bassi, MD, Srivasavi K. Chaganti, MD and Paul A. Gurbel, MD1,*

Sinai Center for Thrombosis Research, Baltimore, Maryland.

Manuscript received July 28, 2006; revised manuscript received September 29, 2006, accepted October 1, 2006.

* Reprint requests and correspondence: Dr. Paul A. Gurbel, Sinai Center for Thrombosis Research, Hoffberger Building, Suite 56, 2401 West Belvedere Avenue, Baltimore, Maryland 21215. (Email: pgurbel{at}lifebridgehealth.org).

Objectives: We sought to determine whether patients receiving chronic clopidogrel therapy undergoing nonemergent stenting who display high on-treatment preprocedural platelet aggregation measured by standard light transmittance aggregometry and thrombelastography (TEG) will be at increased risk for poststenting ischemic events.

Background: Patients exhibiting heightened platelet reactivity to adenosine diphosphate (ADP) might be at increased risk for recurrent ischemic events after coronary stenting.

Methods: A total of 100 consecutive patients receiving chronic antiplatelet therapy consisting of aspirin (325 mg qd) and clopidogrel (75 mg qd) were studied before undergoing nonemergent stenting. Patients were followed for 1 year after coronary stenting for the occurrence of death, myocardial infarction, stent thrombosis, stroke, or ischemia requiring a hospital stay.

Results: All patients were aspirin responsive. Patients with ischemic events (23 of 100, 23%) within 1 year had greater on-treatment prestent ADP-induced platelet aggregation than patients without ischemic events by aggregometry and TEG (p < 0.001 for both measurements). Of patients with an ischemic event, 70% and 87% displayed high on-treatment platelet reactivity at baseline by aggregometry and TEG, respectively. High on-treatment platelet reactivity as measured by aggregometry and TEG were the only variables significantly related to ischemic events (p < 0.001 for both assays). The administration of eptifibatide reduced periprocedural elevation in platelet reactivity, with no significant differences in bleeding events.

Conclusions: Patients receiving chronic clopidogrel therapy undergoing nonemergent percutaneous coronary intervention who exhibit high on-treatment ADP-induced platelet aggregation are at increased risk for postprocedural ischemic events. These findings might have implications for the alteration in clopidogrel maintenance dose and use of glycoprotein IIb/IIIa inhibitors in selected patients.

Abbreviations and Acronyms
  AA = arachidonic acid
  ADP = adenosine diphosphate
  GP = glycoprotein
  HPR = high on-treatment platelet reactivity
  LTA = light transmittance aggregometry
  NPR = normal on-treatment platelet reactivity
  PCI = percutaneous coronary intervention
  TEG = thrombelastograph(y)




This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
G. Dangas, R. Mehran, G. Guagliumi, A. Caixeta, B. Witzenbichler, J. Aoki, J. Z. Peruga, B. R. Brodie, D. Dudek, R. Kornowski, et al.
Role of Clopidogrel Loading Dose in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty: Results From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
J. Am. Coll. Cardiol., October 6, 2009; 54(15): 1438 - 1446.
[Abstract] [Full Text] [PDF]

Home page
 Psychosom. Med.Home page
D. Shimbo, W. Chaplin, S. Kuruvilla, L. T. Wasson, D. Abraham, and M. M. Burg
Hostility and Platelet Reactivity in Individuals Without a History of Cardiovascular Disease Events
Psychosom Med, September 1, 2009; 71(7): 741 - 747.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
A. R. Shuldiner, J. R. O'Connell, K. P. Bliden, A. Gandhi, K. Ryan, R. B. Horenstein, C. M. Damcott, R. Pakyz, U. S. Tantry, Q. Gibson, et al.
Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
JAMA, August 26, 2009; 302(8): 849 - 857.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
C. Verstuyft, T. Simon, and R. B. Kim
Personalized medicine and antiplatelet therapy: ready for prime time?
Eur. Heart J., August 2, 2009; 30(16): 1943 - 1963.
[Full Text] [PDF]

Home page
 HeartHome page
L Bonello, A De Labriolle, M Scheinowitz, G Lemesle, P Roy, D H Steinberg, T L Pinto Slottow, R Pakala, A D Pichard, P Barragan, et al.
Emergence of the concept of platelet reactivity monitoring of response to thienopyridines
Heart, August 1, 2009; 95(15): 1214 - 1219.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
N. B Norgard, K. D Mathews, and G. C Wall
Drug-Drug Interaction Between Clopidogrel and the Proton Pump Inhibitors
Ann. Pharmacother., July 1, 2009; 43(7): 1266 - 1274.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
K.-Y. Chen, S.-W. Rha, Y.-J. Li, K. L. Poddar, Z. Jin, Y. Minami, L. Wang, E. J. Kim, C. G. Park, H. S. Seo, et al.
Triple Versus Dual Antiplatelet Therapy in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Circulation, June 30, 2009; 119(25): 3207 - 3214.
[Abstract] [Full Text] [PDF]

Home page
 Circ Cardiovasc IntervHome page
A. C.Y. To, G. Armstrong, I. Zeng, and M. W.I. Webster
Noncardiac Surgery and Bleeding After Percutaneous Coronary Intervention
Circ Cardiovasc Interv, June 1, 2009; 2(3): 213 - 221.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. J. Price
Bedside Evaluation of Thienopyridine Antiplatelet Therapy
Circulation, May 19, 2009; 119(19): 2625 - 2632.
[Full Text] [PDF]

Home page
 Anesth. Analg.Home page
M. C. Wesley, F. X. McGowan, R. A. Castro, S. Dissanayake, D. Zurakowski, and J. A. DiNardo
The Effect of Milrinone on Platelet Activation as Determined by TEG(R) Platelet MappingTM
Anesth. Analg., May 1, 2009; 108(5): 1425 - 1429.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
W. C. Lau and P. A. Gurbel
The drug-drug interaction between proton pump inhibitors and clopidogrel
Can. Med. Assoc. J., March 31, 2009; 180(7): 699 - 700.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
Y. H. Jeong, S.-W. Lee, B.-R. Choi, I.-S. Kim, M.-K. Seo, C. H. Kwak, J.-Y. Hwang, and S.-W. Park
Randomized Comparison of Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With High Post-Treatment Platelet Reactivity Results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) Randomized Study.
J. Am. Coll. Cardiol., March 31, 2009; 53(13): 1101 - 1109.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
W. Kuliczkowski, A. Witkowski, L. Polonski, C. Watala, K. Filipiak, A. Budaj, J. Golanski, D. Sitkiewicz, J. Pregowski, J. Gorski, et al.
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology
Eur. Heart J., February 2, 2009; 30(4): 426 - 435.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
D. M. Scott, R. M Norwood, and D. Parra
P2Y12 Inhibitors in Cardiovascular Disease: Focus on Prasugrel
Ann. Pharmacother., January 1, 2009; 43(1): 64 - 76.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. Erlinge, C. Varenhorst, O. O. Braun, S. James, K. J. Winters, J. A. Jakubowski, J. T. Brandt, A. Sugidachi, A. Siegbahn, and L. Wallentin
Patients With Poor Responsiveness to Thienopyridine Treatment or With Diabetes Have Lower Levels of Circulating Active Metabolite, but Their Platelets Respond Normally to Active Metabolite Added Ex Vivo
J. Am. Coll. Cardiol., December 9, 2008; 52(24): 1968 - 1977.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. A. Cairns and J. Eikelboom
The Pursuit of Clinically Relevant Measures of Platelet Function After Antiplatelet Drug Therapy
J. Am. Coll. Cardiol., December 9, 2008; 52(24): 1978 - 1980.
[Full Text] [PDF]

Home page
 QJMHome page
R. Bhindi, O. Ormerod, J. Newton, A.P. Banning, and L. Testa
Interaction between statins and clopidogrel: is there anything clinically relevant?
QJM, December 1, 2008; 101(12): 915 - 925.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
G. Patti, A. Nusca, F. Mangiacapra, L. Gatto, A. D'Ambrosio, and G. Di Sciascio
Point-of-Care Measurement of Clopidogrel Responsiveness Predicts Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention: Results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) Study
J. Am. Coll. Cardiol., September 30, 2008; 52(14): 1128 - 1133.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
D. O. Williams and J. D. Abbott
What to Do With Patients Receiving Long-Term Clopidogrel: Reload or Relax?
Circulation, September 16, 2008; 118(12): 1219 - 1222.
[Full Text] [PDF]

Home page
 CirculationHome page
J.-P. Collet, J. Silvain, A. Landivier, M.-L. Tanguy, G. Cayla, A. Bellemain, N. Vignolles, S. Gallier, F. Beygui, A. Pena, et al.
Dose Effect of Clopidogrel Reloading in Patients Already on 75-mg Maintenance Dose: The Reload With Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term With Dual Antiplatelet Therapy (RELOAD) Study
Circulation, September 16, 2008; 118(12): 1225 - 1233.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
Y.-H. Jeong, I.-S. Kim, B.-R. Choi, C. H. Kwak, and J.-Y. Hwang
The optimal threshold of high post-treatment platelet reactivity could be defined by a point-of-care VerifyNow P2Y12 assay
Eur. Heart J., September 1, 2008; 29(17): 2186 - 2187.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
K. P. Bliden, J. DiChiara, L. Lawal, A. Singla, M. J. Antonino, B. A. Baker, W. L. Bailey, U. S. Tantry, and P. A. Gurbel
The Association of Cigarette Smoking With Enhanced Platelet Inhibition by Clopidogrel
J. Am. Coll. Cardiol., August 12, 2008; 52(7): 531 - 533.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
Y. Yano, T. Ohmori, S. Hoshide, S. Madoiwa, K. Yamamoto, T. Katsuki, T. Mitsuhashi, J. Mimuro, K. Shimada, K. Kario, et al.
Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad
Eur. Heart J., July 2, 2008; 29(14): 1729 - 1738.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The year in interventional cardiology.
J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2355 - 2369.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. Trenk, W. Hochholzer, M. F. Fromm, L.-E. Chialda, A. Pahl, C. M. Valina, C. Stratz, P. Schmiebusch, H.-P. Bestehorn, H. J. Buttner, et al.
Cytochrome P450 2C19 681G>A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug-Eluting or Bare-Metal Stents
J. Am. Coll. Cardiol., May 20, 2008; 51(20): 1925 - 1934.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
J.-P. Bassand
Unmet needs in antiplatelet therapy
Eur. Heart J. Suppl., May 1, 2008; 10(suppl_D): D3 - D11.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
L. Wallentin
Dual antiplatelet therapy in the drug-eluting stent era
Eur. Heart J. Suppl., May 1, 2008; 10(suppl_D): D38 - D44.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll Cardiol IntvHome page
D. J. Kereiakes and P. A. Gurbel
Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention
J. Am. Coll. Cardiol. Intv., April 1, 2008; 1(2): 111 - 121.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
P. L. L'Allier, G. Ducrocq, N. Pranno, S. Noble, R. Ibrahim, J. C. Gregoire, F. Azzari, A. Nozza, C. Berry, S. Doucet, et al.
Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study.
J. Am. Coll. Cardiol., March 18, 2008; 51(11): 1066 - 1072.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. D. Michelson
P2Y12 Antagonism: Promises and Challenges
Arterioscler Thromb Vasc Biol, March 1, 2008; 28(3): s33 - s38.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al.
Highlights of the year in JACC 2007.
J. Am. Coll. Cardiol., January 29, 2008; 51(4): 490 - 512.
[Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
C. Gachet and B. Aleil
Testing antiplatelet therapy
Eur. Heart J. Suppl., January 1, 2008; 10(suppl_A): A28 - A34.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
P. A. Gurbel, R. C. Becker, K. G. Mann, S. R. Steinhubl, and A. D. Michelson
Platelet Function Monitoring in Patients With Coronary Artery Disease
J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1822 - 1834.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. J. Angiolillo, E. Bernardo, M. Sabate, P. Jimenez-Quevedo, M. A. Costa, J. Palazuelos, R. Hernandez-Antolin, R. Moreno, J. Escaned, F. Alfonso, et al.
Impact of Platelet Reactivity on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
J. Am. Coll. Cardiol., October 16, 2007; 50(16): 1541 - 1547.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
C. Bode and M. Zehender
The use of antiplatelet agents following percutaneous coronary intervention: focus on late stent thrombosis
Eur. Heart J. Suppl., August 1, 2007; 9(suppl_D): D10 - D19.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. Jaffe and B. H. Strauss
Late and Very Late Thrombosis of Drug-Eluting Stents: Evolving Concepts and Perspectives
J. Am. Coll. Cardiol., July 10, 2007; 50(2): 119 - 127.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. J. Moliterno and C. L. Campbell
Unraveling Questions Surrounding Clopidogrel Resistance and Stent Thrombosis: One Less Snag
J. Am. Coll. Cardiol., June 19, 2007; 49(24): 2318 - 2319.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. T. Dove, D. J. Moliterno, W. D. Weaver, and M. E. Shelton
President's Page: Drug-Eluting Stents in Contemporary Practice--A Call for a Real-World, Open-Entry, Device-Tracking Registry
J. Am. Coll. Cardiol., June 5, 2007; 49(22): 2223 - 2226.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, F. Alfonso, C. Macaya, T. A. Bass, and M. A. Costa
Variability in Individual Responsiveness to Clopidogrel: Clinical Implications, Management, and Future Perspectives
J. Am. Coll. Cardiol., April 10, 2007; 49(14): 1505 - 1516.
[Abstract] [Full Text] [PDF]


 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement